首页> 外文OA文献 >Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

【2h】

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

机译：在II / III阶段乳腺癌中Zoledronic酸的辅助治疗的益处和风险。 10年的Azure随机临床试验随访（Big 01/04）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
R.E. Coleman; M. Collinson; W. Gregory; H. Marshall; R. Bell; D. Dodwell; M. Keane; M. Gil; P. Barrett-Lee; D. Ritchie; A. Bowman; V. Liversedge; R.H. De Boer; J.L. Passos-Coelho; S. OReilly; G. Bertelli; J. Joffe; J.E. Brown; C. Wilson; J.C. Tercero; J. Jean-Mairet; R. Gomis; D. Cameron;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [J] . R.E. Coleman, M. Collinson, W. Gregory, Journal of Bone Oncology . 2018,第4期

机译：唑来膦酸辅助治疗II / III期乳腺癌的益处和风险。 AZURE随机临床试验的10年随访（BIG 01/04）
2. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. [J] . Coleman R, Woodward E, Brown J, Breast cancer research and treatment. . 2011,第2期

机译：一项针对II / III期乳腺癌女性的随机III期试验（AZURE：BIG 01-04）在佐剂治疗期间唑来膦酸的安全性和颌骨骨坏死的发生率。
3. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer [J] . R. Coleman, E. Woodward, J. Brown, Breast Cancer Research and Treatment . 2011,第2期

机译：一项针对II / III期乳腺癌的随机III期试验（AZURE：BIG 01–04）在佐剂治疗期间唑来膦酸的安全性和下颌骨坏死的发生率
4. Results of treatment of the patients with II~(nd)-III~(rd) st. breast cancer by combination of low level laer therapy (LLLT) and surgery (10-year experience) [C] . V.A.Mikhailov, I.N.Densiov, G.A.Frank, Conference on Laser Florence'99: A Window on the Laser Medicine World 28-31 October 1999 Florence, Italy . 1999

机译：II〜（nd）-III〜（rd）st患者的治疗结果。低水平激光疗法（LLLT）和手术相结合的乳腺癌（10年经验）
5. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. [D] . Wang, Ying. 2009

机译：在两个阶段的III期随机临床试验中比较评估生存概率的方法。
6. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [O] . R.E. Coleman, M. Collinson, W. Gregory, 2018

机译：唑来膦酸辅助治疗II / III期乳腺癌的益处和风险。 AZURE随机临床试验的10年随访（BIG 01/04）
7. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer [O] . R. Coleman, E. Woodward, J. Brown, 2011

机译：Zoledronic and的Zoledronic and的安全性和颌骨坏死在随机疗法治疗中的辅助治疗期间（Azure：Big 01-04），患有阶段II / III乳腺癌的妇女

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

著录项

相似文献

相关主题

期刊订阅